share_log

There May Be Some Bright Spots In Liaoning Chengda BiotechnologyLtd's (SHSE:688739) Earnings

There May Be Some Bright Spots In Liaoning Chengda BiotechnologyLtd's (SHSE:688739) Earnings

辽宁成大生物技术有限公司(上海证券交易所股票代码:688739)的收益可能有一些亮点
Simply Wall St ·  04/29 18:22

Soft earnings didn't appear to concern Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) shareholders over the last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

疲软的收益似乎并不令辽宁成大生物技术有限公司感到担忧。, Ltd. 's(上海证券交易所股票代码:688739)股东上周的走势。我们认为,较疲软的标题数字可能会被一些积极的潜在因素所抵消。

earnings-and-revenue-history
SHSE:688739 Earnings and Revenue History April 29th 2024
SHSE: 688739 2024 年 4 月 29 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand Liaoning Chengda BiotechnologyLtd's profit results, we need to consider the CN¥99m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Liaoning Chengda BiotechnologyLtd to produce a higher profit next year, all else being equal.

为了正确了解辽宁成大生物技术有限公司的利润业绩,我们需要考虑归因于不寻常项目的9900万元支出。尽管由于不寻常项目而产生的扣除首先令人失望,但有一线希望。我们调查了数千家上市公司,发现不寻常的物品本质上往往是一次性的。而且,毕竟,这正是会计术语的含义。假设这些不寻常的支出不会再次出现,因此,我们预计辽宁成大生物技术有限公司在其他条件相同的情况下,明年将实现更高的利润。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Liaoning Chengda BiotechnologyLtd's Profit Performance

我们对辽宁成大生物科技有限公司盈利表现的看法

Because unusual items detracted from Liaoning Chengda BiotechnologyLtd's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Liaoning Chengda BiotechnologyLtd's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Liaoning Chengda BiotechnologyLtd at this point in time. Every company has risks, and we've spotted 3 warning signs for Liaoning Chengda BiotechnologyLtd (of which 1 is a bit concerning!) you should know about.

由于不寻常的项目削弱了辽宁成大生物技术有限公司去年的收益,你可能会争辩说,我们可以预期本季度的业绩会有所改善。基于这一观察,我们认为辽宁成大生物技术有限公司的法定利润实际上可能低估了其盈利潜力!但不幸的是,其每股收益实际上在去年有所回落。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。因此,尽管收益质量很重要,但考虑辽宁成大生物科技有限公司目前面临的风险同样重要。每家公司都有风险,我们已经发现了辽宁成大生物技术有限公司的3个警告信号(其中1个有点令人担忧!)你应该知道。

This note has only looked at a single factor that sheds light on the nature of Liaoning Chengda BiotechnologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

这份报告只考虑了揭示辽宁成大生物技术有限公司利润性质的单一因素。但是,还有很多其他方法可以让你对公司的看法。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发